Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group

被引:3
|
作者
Gwyther, SJ
Nielsen, OS
Judson, IR
van Glabbeke, M
Verweij, J
机构
[1] E Surrey Hosp, Surrey & Sussex NHS Trust, Surrey RH1 5RH, England
[2] Aarhus Univ Hosp, DK-800 Aarhus C, Denmark
[3] Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
[4] EORTC Data Ctr, B-1200 Brussels, Belgium
[5] Rotterdam Canc Inst, Daniel den Hoed Klin, NL-3008 AE Rotterdam, Netherlands
[6] Univ Hosp, NL-3008 AE Rotterdam, Netherlands
关键词
claimed responses; independent radiological; review; peer review; response rate;
D O I
10.1097/00001813-200007000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR). Investigators claiming a response submitted the relevant chest radiographs (CXR) or scans to two other members of the STBSG for peer review. The reviewers completed a questionnaire indicating overall response or reasons for rejecting the claimed responses. An independent radiologist also reviewed the cases and he was blinded to the results of the peer review until the study was concluded. Twenty-two patients were reviewed by the radiologist and peer review, and the completed questionnaires were retrospectively reviewed. Two differences were noted, one partial responder (PR) was regarded as stable disease by the radiologist and one PR by peer review was determined a complete response by the radiologist. The radiologist found subsequent evidence of progressive disease in three patients who initially showed a PR, whilst the review group noted only one. This study suggests peer review in this tumor type is a satisfactory method of achieving an accurate, objective RR. [(C) 2000 Lippincott Williams & Wilkins].
引用
收藏
页码:433 / 437
页数:5
相关论文
共 50 条
  • [1] Effect of high-dose ifosfamide in advanced soft tissue sarcomas.: A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    Nielsen, OS
    Judson, I
    van Hoesel, Q
    le Cesne, A
    Keizer, HJ
    Blay, JY
    van Oosterom, A
    Radford, JA
    Svancárová, L
    Krzemienlecki, K
    Hermans, C
    van Glabbeke, M
    Oosterhuis, JW
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (01) : 61 - 67
  • [2] HIGH-DOSE DTIC IN ADVANCED SOFT-TISSUE SARCOMAS IN THE ADULT - A PHASE II STUDY OF THE EORTC SOFT-TISSUE AND BONE-SARCOMA-GROUP
    BUESA, JM
    MOURIDSEN, HT
    VANOOSTEROM, AT
    VERWEIJ, J
    WAGENER, T
    STEWARD, W
    POVEDA, A
    VESTLEV, PM
    THOMAS, D
    SYLVESTER, R
    ANNALS OF ONCOLOGY, 1991, 2 (04) : 307 - 309
  • [3] HIGH-DOSE DTIC IN ADVANCED SOFT-TISSUE SARCOMAS (STS) OF THE ADULT - A PHASE-II STUDY OF THE EORTC SOFT-TISSUE AND BONE SARCOMA GROUP
    BUESA, JM
    MOURIDSEN, H
    VANOOSTEROM, AT
    STEWARD, WT
    VERWEY, J
    THOMAS, D
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (01) : 73 - 73
  • [4] Gemcitabine in advanced adult soft-tissue sarcomas.: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    Svancárová, L
    Blay, JY
    Judson, IR
    van Hoesel, QGCM
    van Oosterom, AT
    le Cesne, A
    Keizer, HJ
    Hermans, C
    van Glabbeke, M
    Verweij, J
    Hogendoorn, PCW
    Nielsen, OS
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (04) : 556 - 559
  • [5] Comparison of peer-review (PR) and independent radiologist (IR) review of claimed responders in a phase II study treating advanced soft tissue sarcoma of the adult with high dose ifosfamide. An EORTC study.
    Gwyther, SJ
    Neilsen, OS
    Judson, IR
    van Glabbeke, M
    Verweij, J
    ANNALS OF ONCOLOGY, 2000, 11 : 126 - 126
  • [6] Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group
    Woll, PJ
    Judson, I
    Lee, SM
    Rodenhuis, S
    Nielsen, OS
    Buesa, JM
    Lorigan, PC
    Leyvraz, S
    Hermans, C
    van Glabbeke, M
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (03) : 410 - 412
  • [7] PHASE-II STUDY OF MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN ADVANCED SOFT-TISSUE SARCOMAS OF THE ADULT - AN EORTC-SOFT-TISSUE-AND-BONE-SARCOMA-GROUP STUDY
    VERWEIJ, J
    KRZEMIENIECKI, K
    KOK, T
    POVEDA, A
    VANPOTTELSBERGHE, C
    VANGLABBEKE, M
    MOURIDSEN, H
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (02) : 208 - 209
  • [8] Exatecan in pretreated adult patients with advanced soft tissue sarcoma:: Results of a phase II -: Study of the EORTC Soft Tissue and Bone Sarcoma Group
    Reichardt, P.
    Nielsen, O. S.
    Bauer, S.
    Hartmann, J. T.
    Schoffski, P.
    Christensen, T. B.
    Pink, D.
    Daugaard, S.
    Marreaud, S.
    van Glabbeke, M.
    Blay, J. Y.
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (06) : 1017 - 1022
  • [9] High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group
    Nielsen, OS
    Dombernowsky, P
    Mouridsen, H
    Crowther, D
    Verweij, J
    Buesa, J
    Steward, W
    Daugaard, S
    van Glabbeke, M
    Kirkpatrick, A
    Tursz, T
    BRITISH JOURNAL OF CANCER, 1998, 78 (12) : 1634 - 1639
  • [10] High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group
    OS Nielsen
    P Dombernowsky
    H Mouridsen
    D Crowther
    J Verweij
    J Buesa
    W Steward
    S Daugaard
    M van Glabbeke
    A Kirkpatrick
    T Tursz
    British Journal of Cancer, 1998, 78 : 1634 - 1639